Sharma Praveen
Consultant Gastroenterologist, Institute of Liver, Gastroenterology & Pancreatico-Biliary Sciences, Sir Ganga Ram Hospital, New Delhi.
J Assoc Physicians India. 2018 Aug;66(8):72-78.
Acid-peptic diseases (APDs) are commonly encountered in clinical practice. The identification of proton pump and the subsequent introduction of proton pump inhibitors (PPIs) can be heralded as a milestone in the treatment of APDs. They have been used for the past 25 years with a good track record of safety. Omeprazole is a well-established and most studied drug in the PPI class.
This review is an objective overview of the efficacy and safety of PPIs in APDs, with special focus on omeprazole.
The efficacy of omeprazole in gastroesophageal reflux disease (GERD) and peptic ulcer disease (PUD), including those caused by non-steroidal antiinflammatory drugs (NSAIDs) is well documented. In clinical studies, the newer, more potent PPIs, used at comparable doses, have not shown greater efficacy than omeprazole. The PPIs are in general well-tolerated. Most of the concerns regarding their long-term safety have been unfounded.
Twenty five years after the introduction of omeprazole, the first of the PPIs, omeprazole has still remained a valuable drug in the armamentarium of clinicians.
酸相关性疾病（APDs）在临床实践中很常见。质子泵的发现以及随后质子泵抑制剂（PPIs）的问世堪称酸相关性疾病治疗中的一个里程碑。在过去25年里它们一直在使用，有着良好的安全记录。奥美拉唑是质子泵抑制剂类中一种成熟且研究最多的药物。
本综述客观概述了质子泵抑制剂在酸相关性疾病中的疗效和安全性，特别关注奥美拉唑。
奥美拉唑在胃食管反流病（GERD）和消化性溃疡病（PUD），包括由非甾体抗炎药（NSAIDs）引起的疾病中的疗效已有充分记录。在临床研究中，以相当剂量使用的更新、更强效的质子泵抑制剂并未显示出比奥美拉唑有更高的疗效。质子泵抑制剂总体耐受性良好。关于其长期安全性的大多数担忧并无根据。
在首个质子泵抑制剂奥美拉唑问世25年后，奥美拉唑在临床医生的药库中仍然是一种有价值的药物。
